Follow-up on the Reimbursement Measure Concerning Proton Pump Inhibitors (PPIs)

07-08-2014 | Médicaments: Usage optimal

Since October 1, 2013, following the implementation of an Institut national d’excellence en santé et en services sociaux (INESSS) recommendation, the total cost of reimbursing proton pump inhibitors (PPIs) has decreased significantly for the public prescription drug insurance plan, from a monthly average of $16.5 million in January 2012 to $8.9 million in March 2014. This is according to Suivi de la mesure de remboursement des inhibiteurs de la pompe à protons (IPP), a follow-up report to the March 2013 public notice, which recommended to the Minister that he give preference to scenarios for reimbursing three or four generic PPIs based on the application of a measure referred to as the maximum payable price (MPP).

Given that there was the oustanding question about patients with short bowel or malabsorption syndrome in the report entitled Follow-up on the Reimbursement Measure Concerning Proton Pump Inhibitors (PPIs), additional information is now available.

REF380

Subscribe to our newsletter now

Subscription